Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAURUS: MS-MRD vs NGS-MRD in Multiple Myeloma
NCT06189833Phase 2Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM). Started Nov 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06189833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189833.